- Home
- RVMD vs ROIV Comparison
RVMD vs ROIV Comparison
Compare RVMD & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVMD
- ROIV
- Stock Information
- Founded
- RVMD 2014
- ROIV 2014
- Country
- RVMD United States
- ROIV United Kingdom
- Employees
- RVMD N/A
- ROIV N/A
- Industry
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- RVMD Health Care
- ROIV Health Care
- Exchange
- RVMD Nasdaq
- ROIV Nasdaq
- Market Cap
- RVMD 10.2B
- ROIV 8.4B
- IPO Year
- RVMD 2020
- ROIV N/A
- Fundamental
- Price
- RVMD $56.86
- ROIV $11.83
- Analyst Decision
- RVMD Strong Buy
- ROIV Strong Buy
- Analyst Count
- RVMD 13
- ROIV 9
- Target Price
- RVMD $57.00
- ROIV $17.69
- AVG Volume (30 Days)
- RVMD 1.6M
- ROIV 4.2M
- Earning Date
- RVMD 11-06-2024
- ROIV 11-12-2024
- Dividend Yield
- RVMD N/A
- ROIV N/A
- EPS Growth
- RVMD N/A
- ROIV N/A
- EPS
- RVMD N/A
- ROIV 5.89
- Revenue
- RVMD $742,000.00
- ROIV $129,128,999.00
- Revenue This Year
- RVMD N/A
- ROIV $48.37
- Revenue Next Year
- RVMD $300.00
- ROIV $13.76
- P/E Ratio
- RVMD N/A
- ROIV $1.95
- Revenue Growth
- RVMD N/A
- ROIV 145.68
- 52 Week Low
- RVMD $20.86
- ROIV $8.61
- 52 Week High
- RVMD $62.40
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- RVMD 61.89
- ROIV 51.97
- Support Level
- RVMD $53.69
- ROIV $11.05
- Resistance Level
- RVMD $62.40
- ROIV $12.05
- Average True Range (ATR)
- RVMD 2.10
- ROIV 0.30
- MACD
- RVMD -0.35
- ROIV -0.02
- Stochastic Oscillator
- RVMD 49.83
- ROIV 61.86
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.